I hastetilfælde kan den berørte medlemsstat suspendere markedsføringen af et lægemiddel, forudsat at agenturet underrettes derom senest den følgende arbejdsdag.
In case of urgency, the Member State concerned may suspend the marketing of a medicinal product provided the Agency is informed at the latest on the following working day.